WUGEN Inc. is a biotechnology company developing a novel CAR-T therapy platform including an “off-the-shelf” fratricide-resistant CAR-T cell therapy for T-cell malignancies. 

Fratricide-resistant off-the-shelf CAR-T

CAR-T targeting T-cell malignancies

Healthy T-cells and malignant T-cells share the same surface proteins (target antigens)

Deletion of the target antigen from the surface of the engineered CAR T-cell, that is derived from a healthy donor T-cell, prevents self-killing (fratricide) while ensuring CAR T-cells kill malignant T-cells

Deletion of the T-cell receptor (TCR) enables the use of T-cells from healthy donors without the risk of life-threatening Graft vs. Host Disease (GvHD)